The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma

Published:2021-01-06 Issue:4 Volume:21 Page:365-372
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Jacob Allen¹^ORCID,Shook Jaret²,Hutson Thomas³

Affiliation:

1. Department of Internal Medicine, Baylor Scott and White Medical Center-Temple, Temple, TX, USA

2. Doctor of Pharmacy Student, Ohio Northern University Raabe College of Pharmacy, Ada, OH, USA

3. Division of Genitourinary Oncology, Charles A. Sammons Cancer Center, Baylor University Medical Center, Texas Oncology, Dallas, TX, USA

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2021.1868994

Reference27 articles.

1. International Agency for Research on Cancer and Cancer Research UK. World kidney cancer factsheet. London: Cancer Research UK; 2019. [cited 2020 Sep 15]. Available from: https://gco.iarc.fr/today/fact-sheets-cancers

2. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

3. The spectrum of renal cell carcinoma in adults

4. Renal cell carcinoma

5. Kidney cancer

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effectiveness of the combination of lenvatinib and everolimus in metastatic renal cell carcinoma in patients with resistance to targeted treatment in real clinical practice;Medical alphabet;2024-05-09

2. Advanced Renal Cell Carcinoma With Inferior Vena Cava Thrombus Treated With a Combination of Preoperative Lenvatinib and Pembrolizumab;Anticancer Research;2024-02-29

3. Insights into lenvatinib resistance: mechanisms, potential biomarkers, and strategies to enhance sensitivity;Medical Oncology;2024-02-21

4. Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma;Frontiers in Oncology;2023-07-27

5. Resistance of Lenvatinib in Hepatocellular Carcinoma;Current Cancer Drug Targets;2022-12